Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C patients receiving interferon without depression at baseline: A systematic review and meta-analysis

摘要

BACKGROUND:Depression complicates interferon-based hepatitis C virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes patient well-being and ability to complete a full course of therapy. As a consequence, the likelihood of achieving a sustained virological response (SVR [ie, permanent viral eradication]) is reduced.